Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals

Treating Septic Shock with Nanoparticle Formulation that Redistributes Nitric Oxide with Dr. Harven DeShield - Vivacelle Bio on the Empowered Patient Podcast with Karen Jagoda

Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S

Surge in Septic Shock Care: Vivacelle’s Innovative Approach

Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock

Vivacelle Bio's President and Chief Innovation Officer to Present Data Highlighting the Company's Late-Stage Clinical Programs at the BIO International Convention 2024

Sepsis is to blame for the 40-year-old mother's unexpected death. It sheds light on broader maternal healthcare issues for Black women.

Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients

Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round

Feds hope to cut sepsis deaths by hitching Medicare payments to treatment stats

The Lancet Journal - Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2

Hypovolemic Shock Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Pharmazz, Perfusion Medical, Vivacelle Bio

Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

(BPRW) Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis

Septic Shock Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – Adrenomed AG, Vivacelle Bio, Inotrem

Harven DeShield in BizCast HQ

Vivacelle Bio - Biotech Executive Conversations

Sepsis And Septic Shock Treatment Market Hitting New Highs By 2028 | VBI-S: Vivacelle Bio, Nangibotide (LR12): Inotrem, Allocetra: Enlivex Therapeutics

Vivacelle Bio named included in 101 top Illinois Biotechnology Companies and Startups - 2021

Hypovolemic Shock Market: Market Analysis, Leading Companies, Emerging Drugs, Epidemiology Forecast and Competitive Analysis by DelveInsight